+44 (0)1865 595230
0 Items

Chikungunya

Chikungunya virus is an Alphavirus that has been causing large scale outbreaks in the Americas since 2013. Clinical symptoms including high fever, rash, headache, vomiting, myalgia, and severe joint pain.

At The Native Antigen Company we offer a wide range of Chikungunya antigens and antibodies to support IVD assay development and vaccine R&D. These include mammalian expressed recombinant Virus-like particles, soluble envelope proteins, cell receptor proteins and neutralising monoclonal antibodies.

Chikungunya background

Chikungunya virus (CHIKV) is a member of the genus Alphavirus in the family Togaviridae. Chikungunya fever is a mosquito-borne disease first identified in Tanzania in 1953. Since 2004 there have been extensive outbreaks in Africa and Asia, and in 2013 the first cases were identified in the Caribbean, and by September 2014 more than 650,000 cases had been reported in the Americas. Chikungunya fever usually starts 2–4 days after CHIKV infection, with clinical symptoms including high fever, rash, headache, vomiting, myalgia, and severe joint pain.

Because the virus is transmitted by the same mosquitos that transmit Dengue Virus and Zika Virus, and the clinical symptoms of infection with the viruses are also similar, it is important to be able to distinguish diagnostically between the different infections.

Chikungunya Antigens

We offer a range of recombinant antigens for Chikungunya virus studies, all prepared using our proprietary mammalian cell expression system. These include our unique Virus-like particles (containing E1, E2 and Capsid proteins), together with soluble E1 and E2 envelope proteins.

The most recent addition to our Chikungunya range is a recombinant MXRA8 protein, which has been shown to be a cell surface receptor mediating viral entry into host cells

Chikungunya Antibodies

Our range of antibodies specific for Chikungunya virus includes monoclonal antibodies binding Capsid protein and to E2 envelope protein. We also offer a polyclonal antibody raised against our Chikungunya Virus-like particles, which binds to Capsid, E1 and E2 proteins.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

A silver-lining from Zika virus?

Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...

Congenital CMV – a problem ignored?

Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...

New Nipah Virus antigens now available from The Native Antigen Company

Infection with Nipah Virus (NiV) was first recognised in Malaysia 1998/1999, where a major outbreak occurred in pigs and humans. NiV infection is now endemic in South Asia and several outbreaks of NiV infection have been reported in India and Bangladesh. Currently an...

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

9 + 5 =

Customer Feedback